A medication commonly used to treat intestinal worms is attracting attention from cancer researchers after a new study found that it may help slow the growth of drug-resistant lung tumors. The surprising discovery suggests that an inexpensive, widely available medicine could potentially become part of future cancer treatment strategies.
The drug, called mebendazole, has been used for decades to treat parasitic worm infections. Now, scientists are investigating whether combining it with existing cancer medications could help overcome one of oncology’s greatest challenges: treatment resistance.
A study published in October 2026 in the scientific journal PLOS ONE found that combining mebendazole with the targeted lung cancer medication gefitinib substantially reduced the viability of resistant cancer cells in laboratory experiments and slowed tumor growth in mice.
Although the findings are promising, the treatment has not been proven effective in human lung cancer patients. PLOS+1
Why Drug-Resistant Lung Cancer Is So Difficult to Treat
Lung cancer remains one of the leading causes of cancer-related deaths worldwide.
One of the most common forms, non-small cell lung cancer (NSCLC), accounts for approximately 85% of lung cancer diagnoses.
Some patients have tumors carrying mutations in a gene called EGFR, or epidermal growth factor receptor. These mutations can cause cancer cells to receive continuous signals encouraging them to grow and multiply.
Targeted medications such as gefitinib work by blocking these signals.
Initially, many patients with susceptible EGFR mutations respond well to targeted treatment. However, cancer cells can develop additional mutations or activate alternative survival mechanisms, allowing tumors to continue growing despite therapy.
This phenomenon, known as acquired drug resistance, is a major obstacle in cancer treatment.
Researchers are therefore exploring combinations of medications that attack cancer cells through different biological mechanisms.
What Is Mebendazole, and Why Are Scientists Interested?
Mebendazole belongs to a class of medications called benzimidazoles.
For decades, doctors have prescribed it to treat intestinal parasites, including pinworms, roundworms, and hookworms.
Its primary antiparasitic action involves interfering with microtubules, tiny structural components that cells need for important functions.
Interestingly, cancer cells also rely on microtubules to divide and reproduce.
Laboratory research has suggested that mebendazole may interfere with cancer-cell division, disrupt cellular structures, and contribute to cell death under certain experimental conditions.
Because the medication already has an established history of medical use, scientists are interested in studying whether it could be repurposed for cancer treatment.
This approach is known as drug repurposing, in which researchers investigate new therapeutic applications for existing medicines.
However, a medication’s established safety for treating parasites does not automatically mean that it is safe or effective at the doses and durations potentially required for cancer therapy. PubMed Central (PMC)+1
The New Study: Combining Two Drugs Against Resistant Cancer
Researchers investigated whether combining mebendazole with gefitinib could weaken lung cancer cells that had already developed resistance to gefitinib.
The two medications act through different biological pathways.
Gefitinib blocks EGFR-related growth signaling, while mebendazole interferes with microtubule function.
The researchers believed that targeting both pathways could make resistant cancer cells more vulnerable to damage.
Their laboratory experiments produced striking results.
Cancer-cell viability after 72 hours
0%25%50%75%100%GefitinibMebendazoleCombination
Approximate cell viability relative to untreated controls; laboratory findings, not patient survival rates.
When the resistant lung cancer cells were exposed to gefitinib alone, approximately 93% remained viable compared with untreated controls.
Mebendazole alone, at the tested low concentration, reduced viability to approximately 80%.
But when researchers combined the two medications, viability dropped to approximately 38%.
The combination was considerably more effective in this particular experimental model than either medication at the tested concentrations.
The researchers also observed increased DNA damage and cellular stress, suggesting that the combination may interfere with the cancer cells’ ability to maintain normal replication processes. PLOS+1
Tumor Growth Slowed Significantly in Animal Experiments
The team subsequently tested the drug combination in mice carrying tumors developed from gefitinib-resistant human lung cancer cells.
The researchers monitored tumor growth over a 40-day period.
The results showed that mice receiving the combination treatment experienced slower tumor growth than mice receiving either medication alone.
The median time required for tumors to double in size was:
| Treatment | Tumor doubling time |
|---|---|
| No treatment | 6.2 days |
| Mebendazole alone | 10.3 days |
| Gefitinib alone | 15.5 days |
| Both medications | 25 days |
The combination extended tumor doubling time approximately fourfold compared with untreated mice.
This was an important observation because it suggested that targeting two different cancer-cell mechanisms could produce a stronger effect than using either drug independently.
However, the tumors were not eliminated, and the experiment did not demonstrate that the combination could cure lung cancer.
Furthermore, animal results cannot reliably predict treatment effectiveness in humans. PLOS+1
Could Mebendazole Help Overcome Cancer Drug Resistance?
One of the most intriguing aspects of this discovery is the possibility that treatment-resistant cancer cells may develop vulnerabilities that other medications can exploit.
Resistance does not necessarily make cancer cells immune to every form of treatment.
Instead, changes that help cancer cells survive one medication may increase their dependence on other cellular processes.
In this study, researchers investigated whether disrupting microtubules while simultaneously blocking EGFR signaling could overwhelm the cancer cells’ ability to cope with stress.
The results support further investigation of this strategy.
However, scientists have not conclusively demonstrated that mebendazole reverses gefitinib resistance. The observed effects might instead reflect additional cellular damage caused by the combination.
Understanding this distinction will be essential before researchers can determine how the treatment might work in patients.
Why This Discovery Could Be Important for Cancer Research
Developing a completely new cancer medication can take many years and require substantial financial investment.
Repurposing an existing medicine potentially offers several advantages.
Researchers may already have information about the drug’s manufacturing process, pharmacology, side effects, and established medical uses.
Mebendazole is also relatively inexpensive compared with many newer cancer medications.
If future clinical trials demonstrate that the combination is both safe and effective, it could potentially offer another treatment option for selected patients with resistant lung cancer.
Nevertheless, affordability and laboratory activity alone do not establish clinical usefulness.
Is Mebendazole Currently Approved to Treat Lung Cancer?
No. Mebendazole is not an established or approved treatment for lung cancer.
The October 2026 findings are preclinical, meaning the experiments involved laboratory-grown cancer cells and animals rather than patients receiving the combination as a validated cancer treatment.
Several major questions remain unanswered.
Researchers must determine whether sufficient amounts of mebendazole can safely reach human tumors, whether the combination causes harmful drug interactions, and which patients might benefit.
They must also investigate whether the findings apply to other forms of treatment-resistant lung cancer, particularly tumors resistant to newer targeted therapies such as osimertinib.
Mebendazole should not be used to self-treat cancer or substituted for prescribed oncology treatment. Its safety in ordinary antiparasitic treatment does not establish safety when used long-term or in experimental cancer combinations.
The Bigger Picture: Could Old Medicines Become New Cancer Treatments?
The study highlights an increasingly important direction in medical research: examining whether familiar medications have previously overlooked therapeutic properties.
Scientists are investigating various existing medications for potential anticancer activity, including drugs originally developed for infections and other conditions.
The appeal is understandable. If a medication already exists, researchers may be able to build on previous scientific knowledge rather than beginning development entirely from scratch.
But discovering that a medication affects cancer cells in a laboratory is only the beginning.
Many substances that produce encouraging preclinical results ultimately fail to demonstrate acceptable safety or meaningful benefits in human trials.
Carefully controlled clinical studies remain necessary before experimental findings can become standard medical treatments.
Final Thoughts
A medication once known primarily for treating intestinal worms has emerged as a potentially interesting candidate in the search for new ways to tackle drug-resistant lung cancer.
The October 2026 research demonstrated that combining mebendazole with gefitinib reduced resistant cancer-cell viability and significantly delayed tumor growth in mice.
These findings suggest that attacking cancer cells through multiple biological pathways may offer opportunities to overcome some forms of treatment resistance.
The discovery does not mean a cheap deworming pill can cure lung cancer. It means researchers have identified a promising experimental combination that deserves further investigation.
For patients facing treatment-resistant cancer, the ultimate question is whether these laboratory and animal findings can eventually translate into safer, more effective therapies.
That answer will require additional research and human clinical trials.
Medical disclaimer: This article is intended for educational purposes only and does not constitute medical advice. Patients should consult their oncology team before considering any medication or changing their prescribed cancer treatment.
